Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.

PARP inhibitors are being developed as therapeutic brokers for most cancers. Greater than six compounds have entered scientific trials. The vast majority of these compounds […]

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Read More

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.

Impaired DNA harm response pathways might create vulnerabilities of most cancers cells that may be exploited therapeutically. One such selective vulnerability is the sensitivity of […]

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Read More